Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Omnicell (OMCL) Shares Repurchased (2011 - 2025)

Omnicell (OMCL) reported Shares Repurchased of $61.9 million for Q3 2025, up 18.65% on a QoQ basis from $52.2 million in Q1 2022.

Omnicell (OMCL) has 7 years of Shares Repurchased data on file, last reported at $61.9 million in Q3 2025.

  • Quarterly Shares Repurchased changed N/A year-over-year to $61.9 million in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $61.9 million (changed N/A YoY) and the FY2025 annual result came in at $77.6 million, changed N/A from the prior year.
  • Shares Repurchased improved to $61.9 million in Q3 2025 per OMCL's latest filing, from $52.2 million in the prior quarter.
  • Across five years, Shares Repurchased topped out at $61.9 million in Q3 2025 and bottomed at $52.2 million in Q1 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares Repurchased (Qtr)
1 Veeva Systems 30.85 Bn 24.28 Bn 622.47 Mn -
2 BrightSpring Health Services 12.29 Bn 11.41 Bn 482.22 Mn 60.00 Mn
3 Healthequity 7.80 Bn 7.48 Bn 256.31 Mn 123.31 Mn
4 Hinge Health 4.82 Bn 4.51 Bn 154.23 Mn 104.97 Mn
5 Doximity 4.21 Bn 3.46 Bn 125.97 Mn 90.53 Mn
6 Waystar Holding 4.18 Bn 4.03 Bn 268.04 Mn -
7 10x Genomics 3.78 Bn 3.24 Bn 106.18 Mn -
8 Privia Health 2.65 Bn 2.28 Bn 595.71 Mn -
9 Omnicell 1.95 Bn 1.78 Bn 140.36 Mn -
10 Teladoc Health 1.42 Bn 672.39 Mn 562.57 Mn -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2025 61.95 Mn
Sep 30, 2025 61.95 Mn
Mar 31, 2022 52.21 Mn
Mar 31, 2022 52.21 Mn
Sep 30, 2015 25.00 Mn
Sep 30, 2015 25.00 Mn
Jun 30, 2015 25.02 Mn
Jun 30, 2015 25.02 Mn
Dec 31, 2014 7.04 Mn
Dec 31, 2014 7.04 Mn
Sep 30, 2014 19.60 Mn
Sep 30, 2014 19.60 Mn
Mar 31, 2014 4.07 Mn
Mar 31, 2014 4.07 Mn
Dec 31, 2013 20.96 Mn
Dec 31, 2013 20.96 Mn
Sep 30, 2012 5.30 Mn
Sep 30, 2012 5.30 Mn
Jun 30, 2012 7.06 Mn
Jun 30, 2012 7.06 Mn
Dec 31, 2011 2.01 Mn
Dec 31, 2011 2.01 Mn
Sep 30, 2011 2.56 Mn
Sep 30, 2011 2.56 Mn
Jun 30, 2011 3.27 Mn
Jun 30, 2011 3.27 Mn
Mar 31, 2011 4.73 Mn
Mar 31, 2011 4.73 Mn